Saturday 17 October 2026
Export BMEA’s income statement to Excel — free account
Biomea Fusion, Inc.
BMEA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 76.5% and free cash flow grew 47.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.87
0.03
+3.57%
Follow BMEA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (164.14%) | (189.44%) | (152.35%) | (209.00%) |
+8 more TTM periods Free account |
|
| (59.14%) | (88.62%) | (89.23%) | (115.59%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(125.18%) | (121.19%) | (131.20%) | (280.88%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.65) | (0.78) | (1.35) | (1.44) | |
Free Cash Flow |
(46.91) | (56.15) | (70.37) | (86.43) | |
Capital Expenditures |
0.28 | 0.22 | — | — | |
| Other line items | |||||
Cash ROIC |
(99.11%) | (88.04%) | (82.44%) | (138.82%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.45 | 1.25 | 1.14 | 0.90 | |
Depreciation/Fixed assets |
11.49 | 14.73 | 9.21 | 9.16 | |
Capex/Depreciation |
0.52 | 0.23 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.65) | (0.78) | (1.35) | (1.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates